8. Recurrence.
| EVLA versus RFA | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yr | |
| EVLA | RFA | |
| Nordon 2011 | No results | |
| Rasmussen 2011 3 yr | 24/144 (17) | 17/147 (12) |
| Recovery 2009 | No results | |
| Shepherd 2010 | No results | |
| Syndor 2017 | Mention 'recurrent symptoms' but do not specify what this entails | |
| EVLA versus EVSA | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yr | |
| EVLA | EVSA | |
| LAST 2014 | No results | |
| EVLA versus UGFS | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yrs | |
| EVLA | UGFS | |
| Magna 2013 1 yr | 9/78 (12) | 21/77 (27) |
| Rasmussen 2011 3 yr | 24/144 (17) | 20/144 (14) |
| Vernermo 2016 | No results | |
| EVLA versus CA | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yrs | |
| EVLA | CA | |
| Calik 2019 1 yr | 5/204 (2) | 2/208 (1) |
| EVLA versus MOCA | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yrs | |
| EVLA | MOCA | |
| Vähäaho 2019 1 yr | 0/33 (0) | 10/55 (18) |
| EVLA versus HL/S (surgery) | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yrs | |
| EVLA | HL/S (surgery) | |
| Darwood 2008a 1 yr | No results | |
| Flessenkämper 2013 2 yr | 20/112 (17.8) | 11/94(11.7) |
| HELP‐1 2011 1 yr | 5/124 (4) | 23/113 (20) |
| Magna 2013 1 yr | 9/78 (12) | 6/68 (9) |
| Pronk 2010 1 yr | 5/62 (8) | 5/68 (7) |
| Rasmussen 2007 2 yr | 18/69 (26) | 25/68 (37) |
| Rasmussen 2011a 3 yr | 24/144 (17) | 22/143 (15) |
| RELACS 2012 2 yr | 28/173 (16) | 33/143 (23) |
| Vernermo 2016 | no results | |
| RFA versus UGFS | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yrs | |
| RFA | UGFS | |
| Rasmussen 2011 | 17/147 (12) | 20/144 (14) |
| RFA versus CA | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yrs | |
| RFA | CA | |
| Morrison 2015 | no results | |
| RFA versus MOCA | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yrs | |
| RFA | MOCA | |
| Lane 2017 | 4/68 (6) | 3/77 (4) |
| MARADONA 2019 2 yr | 21/76 (28) | 12/81 (15) |
| Vähäaho 2019 1 yr | 0/32 (0) | 10/55 (18) |
| RFA versus HL/S (surgery) | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yrs | |
| RFA | HL/S (surgery) | |
| EVOLVeS 2003 2 yr | 5/36 (14) | 6/29 (21) |
| Helmy ElKaffas 2011 2 yr | 12/81 (15) | 9/81 (11) |
| Rasmussen 2011a 3 yr | 17/148 (11) | 22/143 (15) |
| Rautio 2002 2 yr | 5/15 (33) | 2/13 (15) |
| Subramonia 2010 | not reported | |
| UGFS versus HL/S (surgery) | ||
| Study ‐ final time point | Recurrence noted at final time point (%) < 5 yrs | |
| UGFS | HL/S (surgery) | |
| FOAM 2010 2 yr | 75/213 (35) | 37/177 (21) |
| Magna 2013 1 yr | 21/77 (27) | 6/68 (9) |
| Rasmussen 2011a 3 yr | 20/144 (14) | 22/143 (15) |
| Vernermo 2016 | not reported | |
aReported as limbs and not participants
CA: cyanoacrylate glue EVLA: endovenous laser ablation EVSA: endovenous steam ablation HL/S: high ligation and stripping MOCA: mechanochemical ablation RFA: radio frequency ablation UGFS: ultrasound‐guided foam sclerotherapy yr: year(s)